sur NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides Set to Present at PODD 2025 Conference
On October 27, 2025, NanoViricides, Inc. is scheduled to present at the PODD 2025 Conference in Boston. Anil R. Diwan, PhD, the company's President, will discuss their drug pipeline and platform technologies available for licensing. A primary focus is NV-387, a clinical stage drug candidate advancing into Phase II trials for treating MPOX in the Democratic Republic of Congo.
NV-387 shows promise as a broad-spectrum antiviral, notably against RSV, Influenza A, and Coronaviruses. It is positioned as a potential first-line therapy for various respiratory viral infections. The drug's mechanism mimics sulfated proteoglycans, crucial for virus binding, offering a resilient approach against viral evolution.
NanoViricides' technology also extends to a pan-herpesvirus candidate, NV-HHV-1, and an anti-HIV candidate, NV-HIV-1, with both showing promising preclinical results.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NanoViricides, Inc.